Company Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.
The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.
The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019.
RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 31, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Dr. Brian Russell Wong M.D., Ph.D. |
Contact Details
Address: 561 Eccles Avenue South San Francisco, California 94080 United States | |
| Phone | (650) 489-9000 |
| Website | rapt.com |
Stock Details
| Ticker Symbol | RAPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001673772 |
| CUSIP Number | 75382E109 |
| ISIN Number | US75382E1091 |
| Employer ID | 47-3313701 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian Russell Wong M.D., Ph.D. | Chief Executive Officer, President and Director |
| Rodney K. B. Young | Chief Financial Officer, Principal Accounting Officer and Secretary |
| Dr. William Ho M.D., Ph.D. | Chief Medical Officer |
| Steve Young Ph.D. | Vice President of Technology |
| Dr. Dirk G. Brockstedt Ph.D. | Chief Scientific Officer |
| Michael Listgarten | General Counsel |
| Gwen R. Carscadden | Chief Human Resources Officer |
| Dr. Paul Kassner | Senior Vice President of Quantitative and Computational Biology |
| Dr. David Wustrow | Senior Vice President of Drug Discovery and Preclinical Development |
| Jennifer Nicholson | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | ARS | Filing |
| Apr 5, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 5, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 7, 2024 | 10-K | Annual Report |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |